Google
BMEA — BIOMEA FUSION INC (Healthcare >> Biotechnology)
BMEA FAQ
What is BMEA's P/E ratio?
BIOMEA FUSION INC (BMEA) currently trades at a P/E ratio of 19.91.
What is BMEA's ROE?
BIOMEA FUSION INC reports a Return on Equity (ROE) of -240.13%.
What is BMEA's dividend yield?
BIOMEA FUSION INC offers a dividend yield of 0.00%.
What is BMEA's Deepscope Quality Score?
Deepscope rates BMEA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BMEA?
Deepscope's AI Timing Score for BMEA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BMEA belong to?
BIOMEA FUSION INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.15
Price
-0.12
(-9.45%)
Day Change
|
|
|---|
BMEA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.15 |
| PBV / Sector |
4.91 / 4.75
|
| Earning Per Share | -0.56 |
| PE / Sector |
19.91 / 17.65
|
| PEG or PE/Growth / Sector |
-1.87 / 0.52
|
| Average 1M Daily Value |
1.60 M
GREAT
|
| Average 1W Daily Value |
1.85 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-09 09:39:42 |
| Symbol | BMEA |
| Name | BIOMEA FUSION INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 72.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 91.82 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1599 Industrial Road, San Carlos, CA, United States, 94070
Phone: 650 980 9099
Website: https://biomeafusion.com
Sector: Healthcare >> Biotechnology
Description: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
